Developer docs
API playgroundTry for free, no card

Search company profiles

Genomedia

Full company profile

uuid000f6s4

Namestring
Genomedia
Legal namestring
Genomedia株式会社
Websiteurl
genomedia.jp
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Genomedia Inc. (Genomedia株式会社) is a Tokyo-based genomic information services company founded in 2013 that delivers genome analysis and clinical data integration solutions specialized for oncology applications in the Japanese healthcare market. Its core products include (i) Genomedia Front / Genomedia Front Cloud Service, a data management system that integrates clinical information with genomic/mutation data and public database content at patient and clinical-trial levels; (ii) QA Commons Lite, a clinical trial search service that uses a proprietary knowledge database to match cancer patients to drug intervention trials in Japan and the US, deployed at over 140 medical institutions as of September 2023; (iii) genome analysis services covering WGS, WES, and RNASeq workflows run from sample preparation through report creation at the company's sanitary testing facility; and (iv) Virtual Sequencing, a deep learning system that predicts cancer genetic abnormalities such as BRAF V600E and MSI-H from H&E-stained pathology images, co-developed with Yokohama City University and National Cancer Center Hospital East and published in Clinical Cancer Research in 2022. Genomedia holds ISO/IEC 27001:2013 and JIS Q 15001:2017 certifications for information security and privacy management.

Short descriptiontext

Genomedia is a Tokyo-based genomic information company founded in 2013 that provides WGS/WES/RNASeq analysis, clinical-genomic data integration software (Genomedia Front), a cancer clinical trial matching service (QA Commons Lite), and an AI pathology system (Virtual Sequencing), primarily to Japanese cancer genome medical core hospitals and national screening programs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer genome analysis, clinical genomic data, precision medicine software, pathology AI screening, clinical trial matching
Industry6 codes
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLACAIAI
FHIR/HL7 Data Repositories & Canonical Data Models
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Computer Programming, Data Processing, Etc.7370
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Genomics Software & Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Genome Analysis Services
TypeProfessional Services
Description

WGS/WES/RNASeq analysis services for human specimens (tumor, non-tumor, blood specimens, etc.) from sample preparation through report creation, conducted through a sanitary testing facility.

genomedia.jp
2Genomedia® Front (Software/Data Management)
TypeSubscription Recurring
Description

Data management software providing clinical and genome information integration, offered as a service with customization capabilities for medical institutions.

genomedia.jp
3QA Commons Lite Subscription
TypeSubscription Recurring
Description

Clinical trial search service provided to medical institutions, serving over 140 facilities as of September 2023.

genomedia.jp
Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1QA Commons Lite provided to medical institutions
ModelSubscriptionBilling cadenceAnnual
Notes

Service provided to medical institutions targeting cancer genome medical core hospitals and their affiliated facilities

genomedia.jp
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Genomedia® Front
Description

Clinical and genomic data integration management system for secure patient-level and clinical trial-level information management and aggregation.

genomedia.jp
+2 more records
Core offering1 text field

Genomedia provides end-to-end cancer genome analysis services (WGS/WES/RNASeq) at its sanitary testing facility, covering everything from sample preparation to clinical report creation. It complements these services with Genomedia Front, a clinical and genomic data integration management platform (available as a cloud service), QA Commons Lite for cancer clinical trial search, and Virtual Sequencing, an AI-based deep learning system that predicts genetic abnormalities from H&E-stained pathological tissue images. Customers are primarily Japanese cancer genome medical core hospitals, affiliated medical institutions, and national cancer research programs.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Virtual Sequencing achieves AUC >0.90 for 12 pathological features and >0.80 for 27 features in detecting BRAF V600E and MSI-H genetic abnormalities
+3 more records
Product overview1 text field

Genomedia is a biotechnology company offering a portfolio of genome analysis and clinical data management products. The core offerings include: Genomedia Front (data management service for integrating clinical and genome/mutation information with cloud service option), QA Commons Lite (clinical trial search service), genome analysis services (WGS/WES/RNASeq), and Virtual Sequencing (AI-powered screening system for predicting genetic abnormalities from pathological images). The products work together to support cancer genome medicine, from sample analysis through data integration and clinical decision support.

Product and service5 records
1Genomedia Front / Genomedia Front Cloud Service
CategoryClinical-Genomic Data Management Platform (Software / SaaS)
Description

Data management service that integrates clinical information with clinical sequencing/genome and mutation data plus public database information, enabling secure patient-level and clinical trial-level information management and aggregation. Available on-premises and as a cloud service, with customizable fields and proprietary analysis plugin support, sold to medical institutions including cancer genome medical core hospitals and national cancer screening programs.

2QA Commons Lite
CategoryClinical Trial Search SaaS
Description

Subscription-based clinical trial search service for medical institutions that comprehensively organizes and searches Japanese and US cancer clinical trial registry data on drug interventions. Powered by a proprietary knowledge database and matching algorithm; used by over 140 facilities (including cancer genome medical core hospitals and affiliated hospitals) as of September 2023.

3Genome Analysis Service (ゲノム解析サービス)
CategoryLaboratory Genome Analysis Services
Description

Large-scale genome analysis services conducted at a sanitary testing facility for human specimens (tumor, non-tumor, blood samples), including WGS, WES, and RNASeq analysis. Delivered as one-stop execution from sample preparation through software/tool development to clinical report creation, with ongoing R&D on high-speed, high-efficiency realization methods.

4Virtual Sequencing
CategoryAI-Powered Pathology Screening (Software)
Description

Deep learning-based screening system that predicts cancer genetic abnormalities (including BRAF V600E and MSI-H) from H&E-stained pathological tissue images, without requiring sequencing. Uses a two-stage detection architecture: first predicting 33 pathological morphological features, then building high-performance genetic abnormality prediction models.

5Genomedia Front Knowledgebase
CategoryClinical Genomics Knowledge Database
Description

Curated knowledge database that underpins Genomedia Front's drug-mutation-clinical trial matching reports. Comprehensively accumulates and updates cancer-related clinical trial information and drug-gene mutation relationship data to support expert panel interpretation of comprehensive genetic testing results.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1横浜市立大学 (Yokohama City University)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-30
Description

Joint research collaboration with Yokohama City University Graduate School of Medicine Molecular Pathology department (led by Prof. Satoshi Fujii) and National Cancer Center East Hospital (led by Dr. Takayuki Yoshino) to develop Virtual Sequencing system for predicting cancer genetic abnormalities from pathological tissue images. Results published in Clinical Cancer Research.

genomedia.jp
2国立研究開発法人 国立がん研究センター (National Cancer Center Japan)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-09-12
Description

Genomedia provides Genomedia Front Cloud Service to support SCRUM-Japan, the world's largest cancer genome screening infrastructure. The partnership covers LC-SCRUM-Asia and MONSTAR-SCREEN programs, enabling clinical information and clinical sequencing data integration management for nationwide cancer genome screening initiatives.

genomedia.jp
3国立がん研究センター東病院 (National Cancer Center Hospital East)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration partner in Virtual Sequencing development, specifically the gastroenterology department led by Dr. Takayuki Yoshino.

genomedia.jp
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cancer genomics company offering NGS-based tumor profiling (ImmunoID Next) and related analytical services to biopharma and providers. Comparable to Genomedia's WGS/WES/RNASeq analysis services and biomarker interpretation capabilities.

TypeDirect peer
Description

Oncology real-world evidence and clinical-genomic data platform serving health systems and life sciences. Comparable to Genomedia Front's integrated clinical-genomic data management for cancer care and research.

TypeBroad incumbent
Description

Pioneer in comprehensive genomic profiling (FoundationOne CDx) for solid tumors with broad pharma and provider relationships. Competes with Genomedia's sequencing services and clinical interpretation workflows for Japanese hospital accounts.

TypeDirect peer
Description

Liquid biopsy and genomics company providing blood-based tumor profiling (Guardant360) and biopharma data services. Overlaps with Genomedia's cancer genomic profiling and clinical-genomic data infrastructure for screening programs.

5Tempus Labs
TypeDirect peer
Description

AI-driven precision medicine company offering molecular profiling, clinical-genomic data integration, and clinical trial matching for oncology. Directly comparable to Genomedia across analysis services, data management SaaS, and clinical decision support, though at far greater scale and geographic reach.

TypeDirect peer
Description

Molecular profiling and AI-driven precision medicine company offering whole-exome/transcriptome sequencing (MI Profile) and a biopharma data platform. Comparable to Genomedia across WES/RNAseq services and clinical-genomic data integration.

TypeEmerging player
Description

Precision medicine informatics company offering genomic-clinical decision support software and curated knowledge databases for variant and drug interpretation. Closely aligned with Genomedia Front Knowledgebase and QA Commons Lite clinical-trial matching.

TypeDirect peer
Description

Genomic diagnostics company focused on oncology and pulmonology, providing molecular testing and a data platform. Comparable in clinical-genomic decision support and hospital-channel distribution, though primarily tissue-based rather than blood-based profiling.

TypeRegional player
Description

Japanese genomics services company providing microarray- and sequencing-based analysis to pharma and academic customers. Most directly comparable Japanese peer for Genomedia's analysis services and clinical-genomic data offerings.

TypeRegional player
Description

Japanese diagnostics leader offering in-vitro diagnostics, hematology, and increasingly oncology molecular testing. A natural Japan-based competitor and potential acquirer/partner for Genomedia's hospital sequencing services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genomedia

Clinical Genomics Software & Servicesgenomedia.jp

Genomedia is a Tokyo-based genomic information company founded in 2013 that provides WGS/WES/RNASeq analysis, clinical-genomic data integration software (Genomedia Front), a cancer clinical trial matching service (QA Commons Lite), and an AI pathology system (Virtual Sequencing), primarily to Japanese cancer genome medical core hospitals and national screening programs.

What Genomedia does

Genomedia Inc. (Genomedia株式会社) is a Tokyo-based genomic information services company founded in 2013 that delivers genome analysis and clinical data integration solutions specialized for oncology applications in the Japanese healthcare market. Its core products include (i) Genomedia Front / Genomedia Front Cloud Service, a data management system that integrates clinical information with genomic/mutation data and public database content at patient and clinical-trial levels; (ii) QA Commons Lite, a clinical trial search service that uses a proprietary knowledge database to match cancer patients to drug intervention trials in Japan and the US, deployed at over 140 medical institutions as of September 2023; (iii) genome analysis services covering WGS, WES, and RNASeq workflows run from sample preparation through report creation at the company's sanitary testing facility; and (iv) Virtual Sequencing, a deep learning system that predicts cancer genetic abnormalities such as BRAF V600E and MSI-H from H&E-stained pathology images, co-developed with Yokohama City University and National Cancer Center Hospital East and published in Clinical Cancer Research in 2022. Genomedia holds ISO/IEC 27001:2013 and JIS Q 15001:2017 certifications for information security and privacy management.

Genomedia firmographics

Firmographics
Name
Genomedia
Legal name
Genomedia株式会社
Website
https://genomedia.jp
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
1–10 employees
Short description
Genomedia is a Tokyo-based genomic information company founded in 2013 that provides WGS/WES/RNASeq analysis, clinical-genomic data integration software (Genomedia Front), a cancer clinical trial matching service (QA Commons Lite), and an AI pathology system (Virtual Sequencing), primarily to Japanese cancer genome medical core hospitals and national screening programs.
Ownership category
akta.pro rank

Genomedia industry classification

Industry
Product category
Clinical Genomics Software & Services
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), Services-Computer Programming, Data Processing, Etc. (7370), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAA
Genomics & Next-Generation Sequencing (NGS) Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLACAIAI
FHIR/HL7 Data Repositories & Canonical Data Models
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare Data Platforms, Warehousing & Governance
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAAMAJ
Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Cancer genome analysis
  • Clinical genomic data
  • Precision medicine software
  • Pathology AI screening
  • Clinical trial matching

Where Genomedia is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices2 records

Markets served

Genomedia business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Genome Analysis Services: WGS/WES/RNASeq analysis services for human specimens (tumor, non-tumor, blood specimens, etc.) from sample preparation through report creation, conducted through a sanitary testing facility.
  2. Genomedia® Front (Software/Data Management): Data management software providing clinical and genome information integration, offered as a service with customization capabilities for medical institutions.
  3. QA Commons Lite Subscription: Clinical trial search service provided to medical institutions, serving over 140 facilities as of September 2023.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualQA Commons Lite provided to medical institutions

Go-to-market motion1 record

Distribution channels2 records

Genomedia product offering

Product offering

Core offering

Genomedia provides end-to-end cancer genome analysis services (WGS/WES/RNASeq) at its sanitary testing facility, covering everything from sample preparation to clinical report creation. It complements these services with Genomedia Front, a clinical and genomic data integration management platform (available as a cloud service), QA Commons Lite for cancer clinical trial search, and Virtual Sequencing, an AI-based deep learning system that predicts genetic abnormalities from H&E-stained pathological tissue images. Customers are primarily Japanese cancer genome medical core hospitals, affiliated medical institutions, and national cancer research programs.

Product overview

Genomedia is a biotechnology company offering a portfolio of genome analysis and clinical data management products. The core offerings include: Genomedia Front (data management service for integrating clinical and genome/mutation information with cloud service option), QA Commons Lite (clinical trial search service), genome analysis services (WGS/WES/RNASeq), and Virtual Sequencing (AI-powered screening system for predicting genetic abnormalities from pathological images). The products work together to support cancer genome medicine, from sample analysis through data integration and clinical decision support.

Differentiator

Problem solved

Functional benefit

Brands

  • Genomedia® Front: Clinical and genomic data integration management system for secure patient-level and clinical trial-level information management and aggregation.
  • QA Commons Lite
  • Virtual Sequencing

Products and services

  • Genomedia Front / Genomedia Front Cloud Service Data management service that integrates clinical information with clinical sequencing/genome and mutation data plus public database information, enabling secure patient-level and clinical trial-level information management and aggregation. Available on-premises and as a cloud service, with customizable fields and proprietary analysis plugin support, sold to medical institutions including cancer genome medical core hospitals and national cancer screening programs.
  • QA Commons Lite Subscription-based clinical trial search service for medical institutions that comprehensively organizes and searches Japanese and US cancer clinical trial registry data on drug interventions. Powered by a proprietary knowledge database and matching algorithm; used by over 140 facilities (including cancer genome medical core hospitals and affiliated hospitals) as of September 2023.
  • Genome Analysis Service (ゲノム解析サービス) Large-scale genome analysis services conducted at a sanitary testing facility for human specimens (tumor, non-tumor, blood samples), including WGS, WES, and RNASeq analysis. Delivered as one-stop execution from sample preparation through software/tool development to clinical report creation, with ongoing R&D on high-speed, high-efficiency realization methods.
  • Virtual Sequencing Deep learning-based screening system that predicts cancer genetic abnormalities (including BRAF V600E and MSI-H) from H&E-stained pathological tissue images, without requiring sequencing. Uses a two-stage detection architecture: first predicting 33 pathological morphological features, then building high-performance genetic abnormality prediction models.
  • Genomedia Front Knowledgebase Curated knowledge database that underpins Genomedia Front's drug-mutation-clinical trial matching reports. Comprehensively accumulates and updates cancer-related clinical trial information and drug-gene mutation relationship data to support expert panel interpretation of comprehensive genetic testing results.

Quantifiable outcome

  • Virtual Sequencing achieves AUC >0.90 for 12 pathological features and >0.80 for 27 features in detecting BRAF V600E and MSI-H genetic abnormalities
  • +3 more outcomes

Companies that use Genomedia

Customer profile

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Genomedia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Genomedia partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • 横浜市立大学 (Yokohama City University)coreStrategic or Co-development Partner · 30 May 2022Joint research collaboration with Yokohama City University Graduate School of Medicine Molecular Pathology department (led by Prof. Satoshi Fujii) and National Cancer Center East Hospital (led by Dr. Takayuki Yoshino) to develop Virtual Sequencing system for predicting cancer genetic abnormalities from pathological tissue images. Results published in Clinical Cancer Research.
  • 国立研究開発法人 国立がん研究センター (National Cancer Center Japan)coreStrategic or Co-development Partner · 12 September 2019Genomedia provides Genomedia Front Cloud Service to support SCRUM-Japan, the world's largest cancer genome screening infrastructure. The partnership covers LC-SCRUM-Asia and MONSTAR-SCREEN programs, enabling clinical information and clinical sequencing data integration management for nationwide cancer genome screening initiatives.
  • 国立がん研究センター東病院 (National Cancer Center Hospital East)coreStrategic or Co-development PartnerResearch collaboration partner in Virtual Sequencing development, specifically the gastroenterology department led by Dr. Takayuki Yoshino.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Genomedia competitors and assessment

Company assessment

Direct peers

  • Personalis: Cancer genomics company offering NGS-based tumor profiling (ImmunoID Next) and related analytical services to biopharma and providers. Comparable to Genomedia's WGS/WES/RNASeq analysis services and biomarker interpretation capabilities.
  • Syapse: Oncology real-world evidence and clinical-genomic data platform serving health systems and life sciences. Comparable to Genomedia Front's integrated clinical-genomic data management for cancer care and research.
  • Guardant Health: Liquid biopsy and genomics company providing blood-based tumor profiling (Guardant360) and biopharma data services. Overlaps with Genomedia's cancer genomic profiling and clinical-genomic data infrastructure for screening programs.
  • Tempus Labs: AI-driven precision medicine company offering molecular profiling, clinical-genomic data integration, and clinical trial matching for oncology. Directly comparable to Genomedia across analysis services, data management SaaS, and clinical decision support, though at far greater scale and geographic reach.
  • Caris Life Sciences: Molecular profiling and AI-driven precision medicine company offering whole-exome/transcriptome sequencing (MI Profile) and a biopharma data platform. Comparable to Genomedia across WES/RNAseq services and clinical-genomic data integration.
  • Veracyte: Genomic diagnostics company focused on oncology and pulmonology, providing molecular testing and a data platform. Comparable in clinical-genomic decision support and hospital-channel distribution, though primarily tissue-based rather than blood-based profiling.

Broad incumbents

  • Foundation Medicine (Roche): Pioneer in comprehensive genomic profiling (FoundationOne CDx) for solid tumors with broad pharma and provider relationships. Competes with Genomedia's sequencing services and clinical interpretation workflows for Japanese hospital accounts.

Emerging players

  • Molecular Health: Precision medicine informatics company offering genomic-clinical decision support software and curated knowledge databases for variant and drug interpretation. Closely aligned with Genomedia Front Knowledgebase and QA Commons Lite clinical-trial matching.

Regional players

  • DNA Chip Research: Japanese genomics services company providing microarray- and sequencing-based analysis to pharma and academic customers. Most directly comparable Japanese peer for Genomedia's analysis services and clinical-genomic data offerings.
  • Sysmex: Japanese diagnostics leader offering in-vitro diagnostics, hematology, and increasingly oncology molecular testing. A natural Japan-based competitor and potential acquirer/partner for Genomedia's hospital sequencing services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Genomedia social profiles

Digital presence

Genomedia compliance and trust

Trust signal

Compliance2 records

Genomedia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genomedia leadership team

Management profile

Number of profiles

Profiles1 record

Genomedia funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genomedia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomedia

What does Genomedia do?

Genomedia provides end-to-end cancer genome analysis services (WGS/WES/RNASeq) at its sanitary testing facility, covering everything from sample preparation to clinical report creation. It complements these services with Genomedia Front, a clinical and genomic data integration management platform (available as a cloud service), QA Commons Lite for cancer clinical trial search, and Virtual Sequencing, an AI-based deep learning system that predicts genetic abnormalities from H&E-stained pathological tissue images. Customers are primarily Japanese cancer genome medical core hospitals, affiliated medical institutions, and national cancer research programs.

Is Genomedia a public or private company?

Genomedia is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Genomedia founded?

Genomedia was founded in 2013. It employs 1 to 10 people.

Where is Genomedia based?

Genomedia is headquartered in Tokyo, Japan, in the Asia region.

How does Genomedia make money?

Three revenue lines are on record. Genome Analysis Services are the primary driver. The others are genomedia® Front (Software/Data Management) and QA Commons Lite Subscription.

Who are Genomedia's main competitors?

Direct peers on record are Personalis, Syapse, Guardant Health, Tempus Labs, Caris Life Sciences and Veracyte. Foundation Medicine (Roche) is listed as a broad incumbent. Molecular Health is listed as an emerging player. Regional players are DNA Chip Research and Sysmex.

Does Genomedia have an API?

No public API is recorded for Genomedia.

What industry is Genomedia in?

Genomedia's product category is Clinical Genomics Software & Services. Its primary akta.pro industry code is HLAGANAA, Genomics & Next-Generation Sequencing (NGS) Services, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales